Interleukin Genetics Nearly Doubles Revenues in Q4 | GenomeWeb

NEW YORK (GenomeWeb News) — Interleukin Genetics said after the close of market Thursday that its fourth quarter revenues nearly doubled year over year on increased royalty income and genetic testing revenue through the Amway Global sales channel.

Revenues for the three months ended Dec. 31, 2013, were $671,000 compared to $339,000 in the year-ago period. Genetic testing service revenue totaled $424,000 in the quarter, up from $317,000 in Q4 2012, while other revenues jumped to $247,000 from $22,000 in the prior-year period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.